Crossject Société Anonyme (EPA:ALCJ)

Market Cap	42.03M
Revenue (ttm)	4.12M
Net Income (ttm)	-12.80M
Shares Out	47.76M
EPS (ttm)	n/a
PE Ratio	n/a
Forward PE	1.66
Dividend	n/a
Ex-Dividend Date	n/a

Volume	59,492
Average Volume	436,397
Open	0.8880
Previous Close	0.8800
Day's Range	0.8661 - 0.8986
52-Week Range	0.7199 - 2.7500
Beta	0.83
RSI	30.71
Earnings Date	Jun 23, 2025

About Crossject Société Anonyme

Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, a needle-free device for patient-side management disorders self-injectables. Its product pipeline includes Midazolam for epileptic seizure; Naloxone for opioid overdose; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster headaches, as well as Hydrocortisone for acute adrenal crisis and Methotrexate for the treatment of rheumatoid arthritis. The c...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 2001
• Employees: 106
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALCJ

Financial Performance

In 2024, Crossject Société Anonyme's revenue was 4.12 million, an increase of 6.28% compared to the previous year's 3.87 million. Losses were -12.80 million, 48.1% more than in 2023.